Edwards Lifesciences heads into its July 23 Q2 print with an unusually sharp disconnect: a parade of analyst upgrades pulling targets higher while the stock drops to its lowest level in weeks.
The analyst picture is notably constructive ahead of the print. Multiple firms have raised targets in the past two weeks — RBC lifted to $110, Mizuho to $105, and Truist to $95 — pushing the Street consensus target to $99, roughly 15% above the current price of $85.73. The direction of travel is almost uniformly upward, with bullish names pointing to TAVR's 10.6% year-on-year volume growth and TMTT's 48% surge as evidence that the structural heart franchise remains intact. Bulls also expect the company's 8–10% annual sales growth target and projected revenues of $6.4–6.8 billion for 2026 to hold. The one dissenting note comes from Truist, which raised its target but kept a Hold rating — a signal that valuation comfort is not universal even among those turning more positive on the numbers.
Bears have a different read on the same results. The core concern is margin compression: adjusted operating margin came in at 23.7% against a consensus expectation of 25.9%, a meaningful miss driven by elevated SG&A costs. Surgical Structural Heart revenues also undershot expectations slightly, raising questions about whether growth is concentrated enough in TMTT and TAVR to offset weaker legacy lines. The PE multiple at roughly 27x and EV/EBITDA near 21x leave limited room for execution stumbles, and competition in the TAVR space is intensifying. The ORTEX short score has eased from around 32 to 30.4 this month — a low absolute reading — suggesting bears are not pressing hard in the borrow market, but the stock's 7% drop on the week, compared with modest moves for peers like and , points to something specific weighing on EW rather than broad sector pressure. Closest peer fell sharply on the week, so some medtech selling is sector-wide, but EW's underperformance relative to names like (up 1.7% on the week) stands out.
The lending market adds no pressure to this picture. Availability is effectively unlimited — over 7,600% of short interest is available to borrow, and cost to borrow has eased nearly 20% on the week to 0.40%. Short interest at 1.8% of the float is low and falling, down nearly 20% over the past month. Options positioning has actually rotated away from defensiveness, with the put/call ratio at 0.89 — slightly below its 20-day average of 0.93 — suggesting options traders are not loading up on downside protection despite the price weakness.
Insider activity over the past 90 days has been entirely sell-side, including a $2 million disposal by a Vice President in late May and a small CEO sale in June. None of the transactions are large enough to be alarming individually, but the absence of any buying into the weakness is a data point the print will need to address.
The July 23 report will test whether the margin miss from prior quarters is trending toward improvement, or whether the gap between an optimistic analyst consensus and a struggling share price reflects something more durable about EW's cost structure.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
